DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Nihonbashi Life Science HUB

2018 年 10 月 25 日 9:00 上午 - 2018 年 10 月 26 日 6:00 下午

8F, 1-5-5 Nihonbashi-muromachi, Chuo-ku, Tokyo, 103-0022 Japan

7th DIA Cardiac Safety Workshop in Japan

It will be a unique opportunity to learn of and discuss the current state and future directions of CV risk assessments and how to prepare for a new regulatory paradigm.

[Session 3] Abstract Session 1

Session Chair(s)

Naoki  Furuyama, DVM, PhD

Naoki Furuyama, DVM, PhD

Medical Information & Communication, Japan Medical Affairs

Takeda Pharmaceutical Company Limited, Japan

Yuji  Kumagai, MD, PhD

Yuji Kumagai, MD, PhD

Professor, Kitasato Clinical Research Center

Kitasato University Hospital, Japan

Speaker(s)

Robert  Kleiman, MD

Can we rely on automated ECG machine measurements for clinical trial decisions?

Robert Kleiman, MD

ERT, United States

Chief Medical Officer and Vice President, Global Cardiology

Georg  Ferber

Heart Rate Correction When the Drug Affects Heart Rate

Georg Ferber

Statistik Georg Ferber GmbH, Switzerland

Statistical Consultant

Sanae  Yasuda, PhD

Intensive QT investigation as standard practice in early clinical programs

Sanae Yasuda, PhD

Eisai, Japan

Executive Director, Clinical Pharmacology Science, Deep Human Biology Learning

Börje C. Darpö, MD, PhD

Evaluation of a proposed novel biomarker, the JTpeak interval, for evaluation of proarrhythmic liability

Börje C. Darpö, MD, PhD

Clario, Sweden

Chief Scientific Officer, Cardiac Safety

Jorg  Taubel, MD, FFPM

Influence of Food on QT, J-Tpeak and Tpeak - Tend Intervals

Jorg Taubel, MD, FFPM

Richmond Pharmacology, United Kingdom

Chief Executive Officer

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。